Zhonghua Zhong Liu Za Zhi. 2023 Jul 23;45(7):575-583. doi: 10.3760/cma.j.cn112152-20230224-00076.
Chemotherapy-induced neutropenia (CIN) is a common hematological adverse events and dose-limiting toxicities of chemotherapy. CIN may lead to dose reduction and delay of chemotherapeutic agents, febrile neutropenia and severe infection, which results in increased treatment cost, reduced efficacy of chemotherapy, and even life-threatening morbidities. Assessment of risk of CIN, early detection of FN and infection, and proper prevention and treatment play a crucial role in reducing the occurrence of CIN-related morbidities, improving patient treatment safety and anticancer efficacy. Based on evidence and expert opinion, the expert committee of Chinese Anti-Cancer Association issued "the consensus on diagnosis and treatment of chemotherapy-induced neutropenia in China (2023 edition)", which is an update version of the 2019 edition, aiming to provide reference for the diagnosis and treatment of CIN for Chinese oncologists.
化疗引起的中性粒细胞减少症（CIN）是化疗常见的血液学不良事件和剂量限制性毒性。CIN可能导致化疗药物剂量减少和延迟、发热性中性粒细胞减少症及严重感染，从而导致治疗成本增加、化疗疗效降低，甚至出现危及生命的疾病。评估CIN风险、早期发现发热性中性粒细胞减少症和感染以及适当的预防和治疗，对于减少CIN相关疾病的发生、提高患者治疗安全性和抗癌疗效起着至关重要的作用。基于循证医学和专家意见，中国抗癌协会专家委员会发布了《中国化疗所致中性粒细胞减少症诊疗共识（2023年版）》，这是2019年版的更新版本，旨在为中国肿瘤学家对CIN的诊疗提供参考。
